Skip to main content
Top
Published in: Endocrine Pathology 2/2010

01-06-2010

Anti-Saccharomyces cerevisiae Antibodies are Frequent in Type 1 Diabetes

Authors: Wahiba Sakly, Amani Mankaï, Nabil Sakly, Yosra Thabet, Achouak Achour, Leila Ghedira-Besbes, Moncef Jeddi, Ibtissem Ghedira

Published in: Endocrine Pathology | Issue 2/2010

Login to get access

Abstract

Anti-Saccharomyces cerevisiae antibodies (ASCA) have been described in many autoimmune diseases in which there is an increased intestinal permeability. Also in type 1 diabetes (T1D), there is an increased intestinal permeability. Since no data are available about ASCA in T1D, we evaluated, retrospectively, the frequency of ASCA in this disease. ASCA, IgG, and IgA, were determined by ELISA in sera of 224 T1D patients in which coeliac disease has been excluded and 157 healthy control group. The frequency of ASCA (IgG or IgA) was significantly higher in T1D patients than in the control group (24.5% vs. 2.5%, p < 10−7). The same observation was found in children and in adult patients when we compare them to healthy children and blood donors group respectively. Compared to children, adult patients with T1D showed significantly higher frequencies of ASCA of any isotype (38% vs. 13.7%, p < 10−4), both ASCA IgG and IgA (12% vs. 1.6%, p = 0.002), ASCA IgG (35% vs. 9.8%, p < 10−5) and ASCA IgA (15% vs. 5.6%, p = 0.001). The frequency of ASCA was statistically higher in females of all T1D than in males (30.8% vs.17.7%, p = 0.03), in girls than in boys (22% vs.6.2%, p = 0.017), and significantly higher in men than in boys (35.7% vs. 6.2%, p < 10−4). The frequency of ASCA IgG was significantly higher than that of ASCA IgA in all T1D patients (21% vs. 9.8%, p < 0.002), in all females (26.5% vs. 10.2%, p < 0.002), in women (37.9% vs. 12%, p < 0.001). The frequency of ASCA was significantly higher in all long-term T1D than in an inaugural T1D (29% vs. 14.5%, p = 0.019). The same observation was found in adults (45.8% vs. 17.8%, p = 0.01). In long-term T1D patients, ASCA were significantly more frequent in adults than children (45.8% vs. 14.5%, p < 10−4). The frequency of ASCA IgG was significantly higher in long-term T1D than in an inaugural T1D (25.2% vs. 11.6%, p = 0.03). Patients with T1D had a high frequency of ASCA.
Literature
1.
2.
go back to reference Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes 54(Suppl 2):125-36, 2005. Knip M, Veijola R, Virtanen SM, Hyöty H, Vaarala O, Akerblom HK. Environmental triggers and determinants of type 1 diabetes. Diabetes 54(Suppl 2):125-36, 2005.
3.
go back to reference Mokrowiecka A, Daniel P, Słomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology 56:162-6, 2009.PubMed Mokrowiecka A, Daniel P, Słomka M, Majak P, Malecka-Panas E. Clinical utility of serological markers in inflammatory bowel disease. Hepatogastroenterology 56:162-6, 2009.PubMed
4.
go back to reference Ashorn S, Välineva T, Kaukinen K, Ashorn M, Braun J, Raukola H, et al. Serological responses to microbial antigens in celiac disease patients during a gluten-free diet. J Clin Immunol 29:190-5, 2009.CrossRefPubMed Ashorn S, Välineva T, Kaukinen K, Ashorn M, Braun J, Raukola H, et al. Serological responses to microbial antigens in celiac disease patients during a gluten-free diet. J Clin Immunol 29:190-5, 2009.CrossRefPubMed
5.
go back to reference Toumi D, Mankaï A, Belhadj R, Ghedira-Besbes L, Jeddi M, Ghedira I. Anti-Saccharomyces cerevisiae antibodies in coeliac disease. Scand J Gastroenterol 42:821-6, 2007.CrossRefPubMed Toumi D, Mankaï A, Belhadj R, Ghedira-Besbes L, Jeddi M, Ghedira I. Anti-Saccharomyces cerevisiae antibodies in coeliac disease. Scand J Gastroenterol 42:821-6, 2007.CrossRefPubMed
6.
go back to reference Mallant-Hent RCH, Mary B, von Blomberg E, Yuksel Z, Wahab PJ, Gundy C, et al. Disappearance of anti-Saccharomyces cerevisiae antibodies in coeliac disease during a gluten-free diet. Eur J Gastroenterol Hepatol 18:75-8, 2006.CrossRefPubMed Mallant-Hent RCH, Mary B, von Blomberg E, Yuksel Z, Wahab PJ, Gundy C, et al. Disappearance of anti-Saccharomyces cerevisiae antibodies in coeliac disease during a gluten-free diet. Eur J Gastroenterol Hepatol 18:75-8, 2006.CrossRefPubMed
7.
go back to reference Fagoonee S, De Luca L, De Angelis C, Castelli A, Rizzetto M, Pellicano R. Anti-Saccharomyces cerevisiae as unusual antibodies in autoimmune hepatitis. Minerva Gastroenterol Dietol 55:37-40, 2009.PubMed Fagoonee S, De Luca L, De Angelis C, Castelli A, Rizzetto M, Pellicano R. Anti-Saccharomyces cerevisiae as unusual antibodies in autoimmune hepatitis. Minerva Gastroenterol Dietol 55:37-40, 2009.PubMed
8.
go back to reference Sakly W, Jeddi M, Ghedira I. Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig Dis Sci 53:1983-7, 2008.CrossRefPubMed Sakly W, Jeddi M, Ghedira I. Anti-Saccharomyces cerevisiae antibodies in primary biliary cirrhosis. Dig Dis Sci 53:1983-7, 2008.CrossRefPubMed
9.
go back to reference Krause I, Monselise Y, Milo G, Weinberger A. Anti-Saccharomyces cerevisiae antibodies a novel serologic marker for Behcet’s disease. Clin Exp Rheumatol 20(4 Suppl 26):S21-4, 2002.PubMed Krause I, Monselise Y, Milo G, Weinberger A. Anti-Saccharomyces cerevisiae antibodies a novel serologic marker for Behcet’s disease. Clin Exp Rheumatol 20(4 Suppl 26):S21-4, 2002.PubMed
10.
go back to reference Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 47:142-4, 2008. Aydin SZ, Atagunduz P, Temel M, Bicakcigil M, Tasan D, Direskeneli H. Anti-Saccharomyces cerevisiae antibodies (ASCA) in spondyloarthropathies: a reassessment. Rheumatology (Oxford) 47:142-4, 2008.
11.
go back to reference Dai H, Li Z, Zhang Y, Lv P, Gao XM. Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus. Lupus 18:1087-90, 2009.CrossRefPubMed Dai H, Li Z, Zhang Y, Lv P, Gao XM. Elevated levels of serum antibodies against Saccharomyces cerevisiae mannan in patients with systemic lupus erythematosus. Lupus 18:1087-90, 2009.CrossRefPubMed
12.
go back to reference D’Inca R, Annese V, di Leo V, Latiano A, Quaino V, Abazia C, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn’s disease. Aliment Pharmacol Ther 23:1455-61, 2006.CrossRefPubMed D’Inca R, Annese V, di Leo V, Latiano A, Quaino V, Abazia C, et al. Increased intestinal permeability and NOD2 variants in familial and sporadic Crohn’s disease. Aliment Pharmacol Ther 23:1455-61, 2006.CrossRefPubMed
13.
go back to reference Duerksen DR, Wilhelm-Boyles C, Veitch R, Kryszak D, Parry DM. A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet. Dig Dis Sci 55:1026-31, 2009. Duerksen DR, Wilhelm-Boyles C, Veitch R, Kryszak D, Parry DM. A comparison of antibody testing, permeability testing, and zonulin levels with small-bowel biopsy in celiac disease patients on a gluten-free diet. Dig Dis Sci 55:1026-31, 2009.
14.
go back to reference Feld JJ, Meddings J, Heathcote EJ. Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci 51:1607-13, 2006.CrossRefPubMed Feld JJ, Meddings J, Heathcote EJ. Abnormal intestinal permeability in primary biliary cirrhosis. Dig Dis Sci 51:1607-13, 2006.CrossRefPubMed
15.
go back to reference Fresko I, Hamuryudan V, Demir M, Hizli N, Sayman H, Melikoglu M, et al. Intestinal permeability in Behcet’s syndrome. Ann Rheum Dis 60:65-6, 2001.CrossRefPubMed Fresko I, Hamuryudan V, Demir M, Hizli N, Sayman H, Melikoglu M, et al. Intestinal permeability in Behcet’s syndrome. Ann Rheum Dis 60:65-6, 2001.CrossRefPubMed
16.
go back to reference Vaile JH, Meddings JB, Yacyshyn BR, Russell AS, Maksymowych WP. Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives. J Rheumatol 26:128-35, 1999.PubMed Vaile JH, Meddings JB, Yacyshyn BR, Russell AS, Maksymowych WP. Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives. J Rheumatol 26:128-35, 1999.PubMed
17.
go back to reference Visser J, Rozing J, Sapone A, Lammers K, Fasano A. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci 1165:195-205, 2009.CrossRefPubMed Visser J, Rozing J, Sapone A, Lammers K, Fasano A. Tight junctions, intestinal permeability, and autoimmunity: celiac disease and type 1 diabetes paradigms. Ann N Y Acad Sci 1165:195-205, 2009.CrossRefPubMed
18.
go back to reference Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49:2824-7, 2006.CrossRefPubMed Bosi E, Molteni L, Radaelli MG, Folini L, Fermo I, Bazzigaluppi E, et al. Increased intestinal permeability precedes clinical onset of type 1 diabetes. Diabetologia 49:2824-7, 2006.CrossRefPubMed
19.
go back to reference The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-97, 1997. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 20:1183-97, 1997.
20.
go back to reference Mankaï A, Ben Hamouda H, Amri F, Ghedira-Besbes L, Harbi A, Tahar Sfar M, et al. Screening by anti-endomysium antibodies for celiac disease in Tunisian children with type 1 diabetes mellitus. Gastroenterol Clin Biol 31:462-466, 2007PubMedCrossRef Mankaï A, Ben Hamouda H, Amri F, Ghedira-Besbes L, Harbi A, Tahar Sfar M, et al. Screening by anti-endomysium antibodies for celiac disease in Tunisian children with type 1 diabetes mellitus. Gastroenterol Clin Biol 31:462-466, 2007PubMedCrossRef
21.
go back to reference Mankaï A, Sakly W, Landolsi H, Gueddah L, Sriha B, Ayadi A, et al. Tissue transglutaminase antibodies in celiac disease, comparison of an enzyme linked immunosorbent assay and a dot blot assay. Pathol Biol 53:204-9, 2005.CrossRefPubMed Mankaï A, Sakly W, Landolsi H, Gueddah L, Sriha B, Ayadi A, et al. Tissue transglutaminase antibodies in celiac disease, comparison of an enzyme linked immunosorbent assay and a dot blot assay. Pathol Biol 53:204-9, 2005.CrossRefPubMed
22.
go back to reference Fasano A, Not T, Wang W. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in celiac disease. Lancet 355:1518-9, 2000.CrossRefPubMed Fasano A, Not T, Wang W. Zonulin, a newly discovered modulator of intestinal permeability, and its expression in celiac disease. Lancet 355:1518-9, 2000.CrossRefPubMed
23.
go back to reference Franzese A, Lombardi F, Valerio G, Spagnuolo MI. Update on coeliac disease and type 1 diabetes mellitus in childhood. J Pediatr Endocrinol Metab 20:1257-64, 2007.PubMed Franzese A, Lombardi F, Valerio G, Spagnuolo MI. Update on coeliac disease and type 1 diabetes mellitus in childhood. J Pediatr Endocrinol Metab 20:1257-64, 2007.PubMed
24.
go back to reference Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55:1443-9, 2006.CrossRefPubMed Sapone A, de Magistris L, Pietzak M, Clemente MG, Tripathi A, Cucca F, et al. Zonulin upregulation is associated with increased gut permeability in subjects with type 1 diabetes and their relatives. Diabetes 55:1443-9, 2006.CrossRefPubMed
25.
go back to reference Kuitunen M, Saukkonen T, Ilonen J, Akerblom HK, Savilahti E. Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele. Autoimmunity 35:365-58, 2002.CrossRefPubMed Kuitunen M, Saukkonen T, Ilonen J, Akerblom HK, Savilahti E. Intestinal permeability to mannitol and lactulose in children with type 1 diabetes with the HLA-DQB1*02 allele. Autoimmunity 35:365-58, 2002.CrossRefPubMed
26.
go back to reference Pozzilli P, Mesturino CA, Crino A, Gross TM, Jeng LM, Visalli N; IMDIAB Group. Is the process of beta-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males? Eur J Endocrinol 145:757-61, 2001.CrossRefPubMed Pozzilli P, Mesturino CA, Crino A, Gross TM, Jeng LM, Visalli N; IMDIAB Group. Is the process of beta-cell destruction in type 1 diabetes at time of diagnosis more extensive in females than in males? Eur J Endocrinol 145:757-61, 2001.CrossRefPubMed
27.
go back to reference Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E. Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes 52:2287-95, 2003.CrossRefPubMed Westerholm-Ormio M, Vaarala O, Pihkala P, Ilonen J, Savilahti E. Immunologic activity in the small intestinal mucosa of pediatric patients with type 1 diabetes. Diabetes 52:2287-95, 2003.CrossRefPubMed
28.
go back to reference Auricchio R, Paparo F, Maglio M, Franzese A, Lombardi F, Valerio G, et al. In vitro-deranged intestinal immune response to gliadin in type 1 diabetes. Diabetes 53:1680-3, 2004.CrossRefPubMed Auricchio R, Paparo F, Maglio M, Franzese A, Lombardi F, Valerio G, et al. In vitro-deranged intestinal immune response to gliadin in type 1 diabetes. Diabetes 53:1680-3, 2004.CrossRefPubMed
29.
go back to reference Frisk G, Hansson T, Dahlbom I, Tuvemo T. A unifying hypothesis on the development of type 1 diabetes and celiac disease: Gluten consumption may be a shared causative factor. Med Hypotheses 70:1207-9, 2008.CrossRefPubMed Frisk G, Hansson T, Dahlbom I, Tuvemo T. A unifying hypothesis on the development of type 1 diabetes and celiac disease: Gluten consumption may be a shared causative factor. Med Hypotheses 70:1207-9, 2008.CrossRefPubMed
30.
go back to reference Vaarala O, Atkinson MA, Neu J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57:2555-62, 2008.CrossRefPubMed Vaarala O, Atkinson MA, Neu J. The "perfect storm" for type 1 diabetes: the complex interplay between intestinal microbiota, gut permeability, and mucosal immunity. Diabetes 57:2555-62, 2008.CrossRefPubMed
31.
go back to reference Mankaï A, Landolsi H, Chahed A, Gueddah L, Limem M, Ben Abdessalem M, et al. Celiac disease in Tunisia: serological screening in healthy blood donors. Pathol Biol 54:10-3, 2006.CrossRefPubMed Mankaï A, Landolsi H, Chahed A, Gueddah L, Limem M, Ben Abdessalem M, et al. Celiac disease in Tunisia: serological screening in healthy blood donors. Pathol Biol 54:10-3, 2006.CrossRefPubMed
32.
go back to reference Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 359:2767-77, 2008.CrossRefPubMed Smyth DJ, Plagnol V, Walker NM, Cooper JD, Downes K, Yang JH, et al. Shared and distinct genetic variants in type 1 diabetes and celiac disease. N Engl J Med 359:2767-77, 2008.CrossRefPubMed
33.
go back to reference Turley SJ, Lee JW, Dutton-Swain N, Mathis D, Benoist C. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc Natl Acad Sci USA 102:17729-33, 2005.CrossRefPubMed Turley SJ, Lee JW, Dutton-Swain N, Mathis D, Benoist C. Endocrine self and gut non-self intersect in the pancreatic lymph nodes. Proc Natl Acad Sci USA 102:17729-33, 2005.CrossRefPubMed
34.
go back to reference Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab 88:162-5, 2003.CrossRefPubMed Pastore MR, Bazzigaluppi E, Belloni C, Arcovio C, Bonifacio E, Bosi E. Six months of gluten-free diet do not influence autoantibody titers, but improve insulin secretion in subjects at high risk for type 1 diabetes. J Clin Endocrinol Metab 88:162-5, 2003.CrossRefPubMed
35.
go back to reference Standaert-Vitse A, Jouault T, Vandewalle P, Mille C, Seddik M, Sendid B, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology130:1764-75, 2006. Standaert-Vitse A, Jouault T, Vandewalle P, Mille C, Seddik M, Sendid B, et al. Candida albicans is an immunogen for anti-Saccharomyces cerevisiae antibody markers of Crohn’s disease. Gastroenterology130:1764-75, 2006.
36.
go back to reference Willis AM, Coulter WA, Hayes JR, Bell P, Lamey PJ. Factors affecting the adhesion of Candida albicans to epithelial cells of insulin-using diabetes mellitus patients. J Med Microbiol 49:291-3, 2000.PubMed Willis AM, Coulter WA, Hayes JR, Bell P, Lamey PJ. Factors affecting the adhesion of Candida albicans to epithelial cells of insulin-using diabetes mellitus patients. J Med Microbiol 49:291-3, 2000.PubMed
37.
go back to reference Sano H, Terasaki J, Tsutsumi C, Imagawa A, Hanafusa T. A case of fulminant type 1 diabetes mellitus after influenza B infection. Diabetes Res Clin Pract 79:8-9, 2008.CrossRef Sano H, Terasaki J, Tsutsumi C, Imagawa A, Hanafusa T. A case of fulminant type 1 diabetes mellitus after influenza B infection. Diabetes Res Clin Pract 79:8-9, 2008.CrossRef
38.
go back to reference Chiou CC, Chung WH, Hung SI, Yang LC, Hong HS. Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol 54:S14-7, 2006.CrossRefPubMed Chiou CC, Chung WH, Hung SI, Yang LC, Hong HS. Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection. J Am Acad Dermatol 54:S14-7, 2006.CrossRefPubMed
39.
go back to reference Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 104:5115-20, 2007.CrossRefPubMed Dotta F, Censini S, van Halteren AG, Marselli L, Masini M, Dionisi S, et al. Coxsackie B4 virus infection of beta cells and natural killer cell insulitis in recent-onset type 1 diabetic patients. Proc Natl Acad Sci USA 104:5115-20, 2007.CrossRefPubMed
Metadata
Title
Anti-Saccharomyces cerevisiae Antibodies are Frequent in Type 1 Diabetes
Authors
Wahiba Sakly
Amani Mankaï
Nabil Sakly
Yosra Thabet
Achouak Achour
Leila Ghedira-Besbes
Moncef Jeddi
Ibtissem Ghedira
Publication date
01-06-2010
Publisher
Springer US
Published in
Endocrine Pathology / Issue 2/2010
Print ISSN: 1046-3976
Electronic ISSN: 1559-0097
DOI
https://doi.org/10.1007/s12022-010-9118-7

Other articles of this Issue 2/2010

Endocrine Pathology 2/2010 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.